Welcome to Health & Wealth! If you’re new, you can subscribe for free to learn about genomics, life science companies, and my fresh insights on the innovation theme park of biology — delivered directly to your inbox:

Subscribe

Article Highlights

• Natera has surpassed Illumina in market capitalization, becoming the first genomics diagnostics company to eclipse the sequencing giant, while Invitae fell from a $12 billion valuation to bankruptcy and a sale for less than $300 million.
• Natera’s focus on high-margin niches like minimal residual disease (MRD) testing has driven record growth, processing over 1 million MRD tests in 2024 and achieving a 62% gross margin.
• Invitae’s ambition to be a one-stop shop for genetic testing unraveled due to a sprawling portfolio, failed acquisitions, mounting debt, and operational inefficiencies.
• As sequencing costs drop, the shift toward whole genome sequencing could change the rules of the game again, creating opportunities for companies with scale and consumer-focused strategies.

Natera has overtaken Illumina in market capitalization, now valued at $21B versus the sequencing giant’s $13B — marking the first time a genomics-based diagnostics company has eclipsed Illumina, the industry’s long-standing titan.

Meanwhile, Invitae, once valued at $12B at its peak in 2021, has been sold to Labcorp (bankruptcy sale) and Natera (reproductive health assets) for less than $300 million combined.

This isn’t just a story of two companies — it's a case study in how strategic focus can create billion-dollar winners while unchecked ambition can lead to financial ruin.

So, how did these two labs diverge in their paths?

It comes down to their divergent strategies in times of distress. Natera executed a disciplined, high-margin strategy by specializing in reimbursable oncology testing, while Invitae overextended itself with an ambitious but unsustainable vision of genetic testing for all.

Let’s take a closer look.

Natera’s “Go Deep and Specialize” Approach

Natera has honed in on tests that not only address critical clinical needs but also capture a premium in reimbursement. A core driver of growth is their minimal residual testing (MRD) — a test used to detect recurrence in cancer patients who have received therapy. It’s the main thing they focus on during earning calls these days:

“[We have] a pretty big presence from a commercial standpoint in women's health, and we built that over the last 12 years or so… But largely, yes, we're focusing on helping oncology patients, and we see that Signatera is really making an impact on care, and we're seeing that it's at the very early stages, and that's where a lot of the spending is going.”

— Steve Chapman, Natera CEO Q3 2024 Earnings Call

The number of cancers approved has expanded, including colorectal, breast, bladder, lung, skin, ovarian, fallopian, and peritoneal. What’s impressive is the steep growth in volume — in 2024, over 1 million MRD tests were processed, up 200% from the previous year.

Signatera